Phil Vickers Founder of Solu Therapeutics Backed byAlexandria Venture InvestmentsPeter M. Moglia SourcesSolu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic Malignancies — 2025-04 Browse all founders · Browse investors
